Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
January 1, 2025International Journal of Advancement in Life Sciences ResearchOpen Access

Comparative Analysis of Newer Oral Anticoagulants in the Management of Coronary Artery Disease: Safety and Efficacy in an Intensive Care Setting

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMurali Krishna KandukuriKKKarthickeyan Krishnan

Discussion

Loading...

Member takes

Overview

Randomised study shows safety and efficacy of Apixaban and Dabigatran in coronary artery disease, indicating better patient compliance.

Key Points

  • Apixaban and Dabigatran demonstrated improved safety and satisfaction compared to Warfarin.
  • Warfarin was associated with a higher risk of bleeding but lower patient compliance issues.
  • Randomised study compared Warfarin, Apixaban, and Dabigatran in intensive care patients.
  • Individualised anticoagulation strategies may enhance patient outcomes in long-term therapy.

Cite This Study

Kandukuri et al. (2025) studied this question.

synapsesocial.com/papers/68af269bcf1dd9ea359e2586https://doi.org/10.31632/ijalsr.2025.v08i03.017
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of six-month clinical outcomes of patients with venous thromboembolism treated with apixaban, rivaroxaban, edoxaban or dabigatran2026
  2. 2From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe2026
  3. 3Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world-evidence (SIESTA-A study)2025 · 1 citations
  4. 4PERSONALIZED ANTICOAGULANTS: TAILORING THERAPY TO INDIVIDUAL PATIENT'S NEED2025
  5. 5Anticoagulação na Fibrilação Atrial: uma análise integrativa retrospectiva dos riscos hemorrágicos de Apixabana e Varfarina2025